MedTrace Logo

Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study

NCT00864786 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2009-03-23

No results posted yet for this study

Summary

Multiple dose safety and pharmacokinetics in healthy male subjects

Conditions

Interventions

DRUG

PF03635659

Inhaled doses of 200 mcgQD

DRUG

PF03635659

Inhaled doses of 600 mcg QD

DRUG

PF03635659

Inhaled doses of 1000 mcg QD

DRUG

PF03635659

Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.

DRUG

PF03635659

Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00864786 on ClinicalTrials.gov